| Bioactivity | RCGD423 is a gp130 modulator, which prevents articular cartilage degeneration and promotes repair. | ||||||||||||
| Invitro | RCGD423 is a gp130 modulator, which prevents articular cartilage degeneration and promotes repair[1]. | ||||||||||||
| In Vivo | RCGD423 greatly reduces chondrocyte hypertrophy, loss and degeneration while increasing chondrocyte proliferation beyond that observed in response to injury in a rat partial meniscectomy model. Moreover, RCGD 423 improves cartilage healing in a rat full-thickness osteochondral defect model, increasing proliferation of mesenchymal cells in the defect and also inhibiting breakdown of cartilage matrix in de novo generated cartilage[1]. | ||||||||||||
| Name | RCGD423 | ||||||||||||
| CAS | 108237-91-8 | ||||||||||||
| Formula | C15H11BrN2S | ||||||||||||
| Molar Mass | 331.23 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Shkhyan R, et al. Drug-induced modulation of gp130 signalling prevents articular cartilage degeneration and promotes repair. Ann Rheum Dis. 2018 May;77(5):760-769. |